08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Teva sales and marketing update

Teva launched a generic version of amlodipine/valsartan/hydrochlorothiazide in the U.S. to treat hypertension. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets the combination of the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan and the...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

Ipsen, Novartis deal

Ipsen said in its 3Q12 earnings that in April it terminated a January 2009 deal with Novartis to co-promote the pharma's Exforge amlodipine/valsartan in France to treat hypertension. Ipsen said the termination triggered a €4...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Novartis pharmaceuticals news

Novartis will enter into a five-year corporate integrity agreement with HHS's Office of Inspector General. In January, Novartis agreed to plead guilty to a misdemeanor violation of the U.S. Food, Drug and Cosmetic Act and...
07:00 , Apr 5, 2010 |  BioCentury  |  Finance

1Q Approvals/1Q Setbacks

1Q Approvals/1Q Setbacks Selected first quarter product approvals Company Approval Acorda Therapeutics Inc. (NASDAQ:ACOR) FDA approves Ampyra dalfampridine (formerly Fampridine-SR) to improve walking ability in patients with multiple sclerosis (MS) Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) FDA...
08:00 , Feb 1, 2010 |  BioCentury  |  Strategy

57 flavors of experience

The announcement that pharma industry newcomer Joe Jimenez will take over the CEO post at Novartis AG has sparked speculation that cost-cutting will follow. But a look at his track record in consumer goods reveals...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Clinical News

Exforge amlodipine/valsartan regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Exforge valsartan/amlodipine from Novartis to treat high blood pressure. The company expects to launch the combination of calcium channel blocker amlodipine and angiotensin receptor blocker valsartan,...
01:02 , Jan 21, 2010 |  BC Extra  |  Company News

Japan approves three Novartis drugs

Japan's Ministry of Health, Labor and Welfare (MHLW) approved three drugs from Novartis AG (NYSE:NVS; SIX:NOVN), including Equa vildagliptin to treat Type II diabetes. Equa is a dipeptidyl peptidase-4 (DPP-4) inhibitor. The agency also approved...
08:00 , Jan 4, 2010 |  BioCentury  |  Finance

4Q approvals

4Q approvals Company Approval Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)/ Eli Lilly and Co. (NYSE:LLY) FDA approves Byetta exenatide to include monotherapy in Type II diabetes AstraZeneca plc (LSE:AZN; NYSE:AZN) FDA approves once-daily Seroquel XR quetiapine as...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

Exforge HCT regulatory update

The European Commission approved an MAA from Novartis AG for Exforge HCT amlodipine/valsartan/hydrochlorothiazide as substitution therapy to treat essential hypertension in adults whose blood pressure is adequately controlled on the combination of amlodipine, valsartin and...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Company News

UCB, Novartis sales and marketing update

UCB and Novartis extended to 2014 a co-distribution agreement for cardiovascular drug Provas valsartan in Germany. UCB also received exclusive, German rights to the pharma's hypertension drugs Dafiro valsartan/amlodipine and Dafiro HCT. Further terms were...